BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eberhardson M, Söderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Olén O. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther 2017;46:589-98. [DOI: 10.1111/apt.14224] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
2 Ashton JJ, Beattie RM. Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable? Aliment Pharmacol Ther 2019;50:842-3. [PMID: 31532558 DOI: 10.1111/apt.15482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Müller C, Bergmann M, Stift A, Argeny S, Speake D, Unger L, Riss S. Restoration of intestinal continuity after stoma formation for Crohn’s disease in the era of biological therapy: A retrospective cohort study. Wien Klin Wochenschr 2020;132:12-8. [DOI: 10.1007/s00508-019-01586-9] [Reference Citation Analysis]
4 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Bröms G, Söderling J, Sachs MC, Halfvarson J, Myrelid P, Ludvigsson JF, Everhov ÅH, Olén O; SWIBREG study group. Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study. Scand J Gastroenterol 2021;56:410-21. [PMID: 33632044 DOI: 10.1080/00365521.2021.1884894] [Reference Citation Analysis]
6 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Zhao M, Sall Jensen M, Knudsen T, Kelsen J, Coskun M, Kjellberg J, Burisch J. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther 2021. [PMID: 34881439 DOI: 10.1111/apt.16723] [Reference Citation Analysis]
8 Faiz O, Worley G. Is the need for inflammatory bowel disease surgery diminishing in the biologic era? Colorectal Dis 2019;21:259-60. [PMID: 30821915 DOI: 10.1111/codi.14588] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kalman TD, Everhov ÅH, Nordenvall C, Sachs MC, Halfvarson J, Ekbom A, Ludvigsson JF, Myrelid P, Olén O. Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014. British Journal of Surgery 2020;107:1529-38. [DOI: 10.1002/bjs.11659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Qvist N, Vadstrup K, Alulis S, Borsi A, Munkholm P, Olsen J. Increased use of biologics in the era of TNF-α inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based study from 2003-2016. Scand J Gastroenterol 2021;56:537-44. [PMID: 33736551 DOI: 10.1080/00365521.2021.1897670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ashton JJ, Borca F, Mossotto E, Coelho T, Batra A, Afzal NA, Phan HTT, Stanton M, Ennis S, Beattie RM. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther 2019;49:398-407. [PMID: 30628109 DOI: 10.1111/apt.15094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
12 Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, Biviano I, Naldini S, Mumolo MG, De Nigris F, Calella F, Bagnoli S, Minciotti M, Maltinti S, Rentini S, Ceccarelli L, Lionetti P, Milla M, Costa F. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Inflamm Bowel Dis 2021:izab027. [PMID: 33570142 DOI: 10.1093/ibd/izab027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Levin A, Risto A, Myrelid P. The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100740. [DOI: 10.1016/j.scrs.2020.100740] [Reference Citation Analysis]
14 Kamperidis N, Middleton P, Tyrrell T, Stasinos I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol 2019;10:330-6. [PMID: 31682652 DOI: 10.1136/flgastro-2018-101024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Burr NE, Lord R, Hull MA, Subramanian V. Decreasing Risk of First and Subsequent Surgeries in Patients with Crohn's Disease in England From 1994 through 2013. Clin Gastroenterol Hepatol. 2019;17:2042-2049.e4. [PMID: 30583051 DOI: 10.1016/j.cgh.2018.12.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
16 Eberhardson M, Söderling JK, Olén O. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply. Aliment Pharmacol Ther 2018;47:147-8. [PMID: 29226402 DOI: 10.1111/apt.14398] [Reference Citation Analysis]
17 Everhov ÅH, Khalili H, Askling J, Myrelid P, Ludvigsson JF, Halfvarson J, Nordenvall C, Söderling J, Olén O, Neovius M. Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease. J Crohns Colitis 2018;12:1418-28. [PMID: 30165593 DOI: 10.1093/ecco-jcc/jjy123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Endo K, Kakuta Y, Moroi R, Yamamoto K, Shiga H, Kuroha M, Naito T, Kinouchi Y, Masamune A. TL1A (TNFSF15) genotype affects the long-term therapeutic outcomes of anti-TNFα antibodies for Crohn's disease patients. JGH Open 2020;4:1108-13. [PMID: 33319044 DOI: 10.1002/jgh3.12398] [Reference Citation Analysis]
19 Rispo A, Imperatore N, Testa A, Bucci L, Luglio G, De Palma GD, Rea M, Nardone OM, Caporaso N, Castiglione F. Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort. J Crohns Colitis. 2018;12:784-793. [PMID: 29528382 DOI: 10.1093/ecco-jcc/jjy032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
20 Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J; SWIBREG study group. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther 2021;54:931-43. [PMID: 34286871 DOI: 10.1111/apt.16525] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tarnok A, Kiss Z, Kadenczki O, Veres G. Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opin Biol Ther 2019;19:181-96. [PMID: 30601083 DOI: 10.1080/14712598.2019.1564034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ribaldone DG, Saracco G, Astegiano M, Pellicano R. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Aliment Pharmacol Ther 2018;47:146-7. [PMID: 29226397 DOI: 10.1111/apt.14321] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]